Anastrozole Increases Predicted Adult Height of Short Adolescent Males Treated with Growth Hormone: A Randomized, Placebo-Controlled, Multicenter Trial for One to Three Years

Mauras, Nelly; Pijem, Lilliam Gonzalez de; Hsiang, Helen Y.; Desrosiers, Paul; Rapaport, Robert; Schwartz, I. David; Klein, Karen Oerter; Singh, Ravinder J.; Miyamoto, A.; Bishop, Kim

doi:10.1210/jc.2007-1559

Cited by 126 publications

(90 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Over the past decades there has been a dramatic rise in the age-adjusted incidence of cutaneous squamous cell carcinoma (SCC) in Western countries [1,2,3], which has been associated with increased ultraviolet light exposure, due to lifestyle and global environmental changes [4,5,6]. Morbidity and costs associated with the treatment of cutaneous SCC have an important impact on health systems in areas with a higher incidence [7].…”

Section: Introductionmentioning

confidence: 99%

Skin Cancer Knowledge and Preventive Behaviors among Patients with a Recent History of Cutaneous Squamous Cell Carcinoma

et al. 2008

View full text Add to dashboard Cite

Aims: To evaluate skin cancer knowledge and preventive behaviors of patients recently treated for cutaneous squamous cell carcinoma (SCC) and to examine the factors associated with the adoption of preventive behaviors. Methods: Telephone survey on 315 SCC patients treated at a large dermatological hospital in Italy, evaluating skin cancer knowledge, sun protection and skin examination practices as well as medical recommendations received after SCC removal. Results: Skin cancer knowledge was fair/low for 48.9% of the participants. Doctors were the main source of skin cancer information for 24.4% of the patients. Of the patients assessed ≧12 months after SCC removal, 32.7% reported a total skin examination after removal. Of the participants, 41.6% never/rarely used sunscreens. In a multivariate analysis, the likelihood of having complete skin examinations was associated with a doctor’s advice to have an examination (odds ratio, OR = 2.29; 95% confidence interval, CI = 1.2–4.4), a higher knowledge level (OR = 2.05; 95% CI = 1.1–3.8) and past skin examinations (OR = 3.62; 95% CI = 1.9–7.0). Doctor’s recommendations increased the likelihood of adopting preventive behaviors. Conclusions: We found substantial knowledge gaps and limited adoption of skin cancer prevention, highlighting the need for interventions promoting knowledge and preventive behaviors, particularly among higher-risk patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Skin Cancer Knowledge and Preventive Behaviors among Patients with a Recent History of Cutaneous Squamous Cell Carcinoma

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Although only short-term follow-up is still available, these controlled clinical trials have provided a good safety profile for treatment with aromatase inhibitors. No adverse effects have been demonstrated on glucose, plasma lipid concentrations, and insulin sensitivity (20,23), spermatogenesis (24), and cognitive function (25). Additionally, aromatase inhibitors did not induce detrimental effects on bone mineral density (19,20,26).…”

Section: Discussionmentioning

confidence: 93%

“…No adverse effects have been demonstrated on glucose, plasma lipid concentrations, and insulin sensitivity (20,23), spermatogenesis (24), and cognitive function (25). Additionally, aromatase inhibitors did not induce detrimental effects on bone mineral density (19,20,26). A more recent report suggested that boys with idiopathic short stature treated with letrozole might be predisposed to asymptomatic vertebral wedge deformities (27), although the relevance of these findings is unknown.…”

Section: Discussionmentioning

confidence: 99%

“…These drugs inhibit the biosynthesis of estrogens by blocking aromatase, the rate-limiting enzyme in the conversion of androgens to estrogens. The most compelling evidence supporting the use of aromatase inhibitors as growth-promoting agents comes from four randomized, double-blinded, placebo-controlled trials conducted in male subjects with GH deficiency, (18,19,20,21). All these studies showed that treatment with aromatase inhibitors effectively delays bone maturation and increases predicted adult height.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Combined treatment with GH and anastrozole in a pubertal boy with Cushing's disease and postsurgical GH deficiency

Boronat

Marrero²,

López-Plasencia³

et al. 2012

European Journal of Endocrinology

View full text Add to dashboard Cite

Growth failure is a characteristic manifestation of pediatric Cushing's disease. Catch-up growth is usually incomplete after cure of the disease, and final height is often compromised. Possible mechanisms for this phenomenon include postoperative persistence of GH hyposecretion and absence of retardation of bone maturation in spite of GH deficiency. This report describes the outcome in the case of a boy with Cushing's disease for whom GH replacement therapy was combined with anastrozole, an aromatase inhibitor, in order to delay skeletal maturation and extend the available time for linear growth. The case of a 14 years 4-months-old pubertal male (Tanner stage III) with GH deficiency after successful surgical treatment of Cushing's disease is presented. His height was 147.2 cm (K2.34 SDS), and his midparental target height 171.2 cm (K0.95 SDS). Bone age was 13.5 years and predicted adult height 163.2 cm (K2.2 SDS). Combined treatment was administered for 2.5 years. GH was maintained up to age 18 years. Anastrozole induced a substantial deceleration of bone age. Near-final height at 18 years was 169.5 cm (K1.07 SDS). Puberty progressed normally. Compared with population reference data, bone mineral density before GH plus anastrozole treatment was K4.07 SDS in the lumbar spine and K1.85 SDS in the femoral neck. These measures increased to K1.95 and K0.89 SDSs respectively, at 18 years, when GH was discontinued. Combined treatment with GH and aromatase inhibitors could be a therapeutic alternative to improve the stature of pubertal boys with Cushing's disease and postsurgical GH deficiency.

show abstract

“…BHE'de BH tedavisine ek olarak erkeklerde aromataz inhibitörü tedavisi ile çalış-malar olmakla beraber, yeterli etkinlik ve güvenirlik verisi yoktur ve rutin uygulama önerilmemektedir (41) . Sonuç olarak, puberteye kısa boy ile giren BHE tanılı çocuklarda, toplam pubertal boy kazanımını artırmak hala zor olduğundan, optimal tedavi prepubertal dönemde büyümenin yakalanması ve puberte başla-madan normal boya erişime olanak sağlayan tedavi olacaktır.…”

Section: Toplam Pubertal Büyümeyi Artırmaya Yönelik Tedavi Yaklaşımlarıunclassified

Optimizing growth hormone threapy in chilhood growth hormone defiency

Darendelıler¹

2016

Cocuk Dergisi

View full text Add to dashboard Cite

show abstract

Anastrozole Increases Predicted Adult Height of Short Adolescent Males Treated with Growth Hormone: A Randomized, Placebo-Controlled, Multicenter Trial for One to Three Years

Cited by 126 publications

References 47 publications

Skin Cancer Knowledge and Preventive Behaviors among Patients with a Recent History of Cutaneous Squamous Cell Carcinoma

Skin Cancer Knowledge and Preventive Behaviors among Patients with a Recent History of Cutaneous Squamous Cell Carcinoma

Combined treatment with GH and anastrozole in a pubertal boy with Cushing's disease and postsurgical GH deficiency

Optimizing growth hormone threapy in chilhood growth hormone defiency

Contact Info

Product

Resources

About